I型干扰素抑制对系统性红斑狼疮心脏代谢疾病标志物的调节
本研究基于MUSE IIb期试验,评估anifrolumab(I型干扰素受体阻断抗体)对比安慰剂对SLE患者中性粒细胞胞外诱捕网(NET)形成及心脏代谢疾病标志物的影响。结果显示anifrolumab显著降低NET复合物和GlycA、改善胆固醇外流能力(CEC),并降低TNF和IL-10水平,而安慰剂无改善。提示I型干扰素通路抑制可能降低SLE患者心血管风险。
要点
- SLE患者NET复合物、IL-10、CEC和GlycA较健康对照显著异常。
- anifrolumab较基线显著降低NET复合物和GlycA并改善CEC(P<0.05)。
- anifrolumab较安慰剂显著降低TNF和IL-10水平(P<0.05)。
核心结论
- I型干扰素在调节SLE血管病变相关因素中起关键作用,抑制该通路可能降低SLE患者心血管风险。
研究设计与样本
- 基于MUSE IIb期随机试验,纳入中重度SLE患者305例,健康对照10-20例,治疗组anifrolumab 300mg 99例、安慰剂102例。
主要发现
- NET复合物及TNF、IL-10水平与I型干扰素通路活性程度相关。
- SLE患者NET复合物和IL-10较健康对照上调(P<0.008)。
- SLE患者CEC和GlycA较健康对照异常(P<0.001)。
- anifrolumab较基线显著降低NET复合物和GlycA并改善CEC(P<0.05),安慰剂无改善。
- anifrolumab较安慰剂显著降低TNF和IL-10(P<0.05)。
关键数值与推荐
- 基线采用21基因干扰素基因签名面板检测并动态监测。
- 血清蛋白采用多重免疫分析或超灵敏Simoa法测定。
临床怎么用
- 对中重度SLE患者,anifrolumab可能通过抑制I型干扰素通路改善心脏代谢标志物,提示潜在心血管获益。
局限性
- 研究为IIb期试验的样本分析,健康对照仅10-20例,心血管风险降低为间接推测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Neutrophil dysregulation and the type I interferon (IFN) axis have been proposed to contribute to premature cardiovascular disease, a leading cause of mortality in patients with systemic lupus erythematosus (SLE). In the present study, we evaluated the ability of anifrolumab, a type I IFN receptor-blocking antibody, to reduce neutrophil extracellular trap (NET) formation and modulate cardiometabolic disease markers in comparison to placebo. METHODS: Study subjects comprised patients with moderate-to-severe SLE who were enrolled in phase IIb of the MUSE trial (A Phase II, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus), with healthy individuals as controls. Blood samples were collected from SLE patients (n = 305) and healthy controls (n = 10-20) before the initiation of treatment (baseline) and from SLE patients after they had been treated with 300 mg of anifrolumab (n = 99) or placebo (n = 102). Baseline IFN gene signature test status was determined, and the IFN gene signature (21-gene panel) was monitored over time. Serum proteins were measured by multiplex immunoassay or ultrasensitive Simoa assay. NET complexes, cholesterol efflux capacity (CEC), and glycoprotein acetylation (GlycA) and other lipid parameters were assessed in plasma. RESULTS: Formation of NET complexes and levels of tumor necrosis factor (TNF) and interleukin-10 (IL-10) were correlated with extent of type I IFN pathway activity. NET complexes and IL-10 levels were up-regulated in SLE patients compared to healthy controls (P < 0.008). The cardiometabolic disease markers CEC and GlycA were also found to be dysregulated in patients with SLE (P < 0.001 versus healthy controls). Type I IFN receptor inhibition with anifrolumab significantly reduced NET complexes and GlycA and improved CEC compared to baseline (P < 0.05) whereas no improvements were seen with placebo. Levels of TNF and IL-10 were reduced with anifrolumab compared to placebo (P < 0.05). CONCLUSION: These data support a key role for type I IFNs in modulating factors contributing to SLE vasculopathy and suggest that inhibition of this pathway could decrease cardiovascular risk in individuals with SLE.
引用
- Casey KA, Smith MA, Sinibaldi D, et al. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2021. PMID: 32909675. doi:10.1002/art.41518
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。